Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

First International Summit on Interventional Pharmacoeconomics

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Welcome and Introduction to Vi3C

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Dec

Today In Oncology

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Related Videos

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Welcome and Introduction to Vi3C

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Large AI Breast Cancer Screening Trial Increases Detection Rate

P-RAD Trial Shows Increased T-Cell Infiltration With Preoperative Radiation Added to Anti-PD-1 Therapy in Early Breast Cancer

Regional Control Unchanged by Avoiding Sentinel Lymph Node Biopsy in Early Node-Negative Breast Cancer

Sacituzumab Govitecan vs Standard of Care for Certain Endocrine Therapy-Refractory Advanced Breast Cancers

Phase III Trial Shows No Oncologic Benefit From Routine Preoperative MRI for Some Early Breast Cancers